The European Commission’s investigation into the behaviour of companies operating in the pharmaceutical sector in the European Union culminated in the publication of a final report on July 8, 2009. Duncan Curley looks at the implications.
In the face of spiralling European drugs bills, the rationale for the European Commission’s initial investigation was to learn more about company practices that cause delays to the market entry of cheaper generic medicines. The commission presented its preliminary report in November 2008.
On matters such as patent filing strategies and patent litigation (delaying) tactics, this preliminary report received a largely hostile response from originator pharmaceutical companies.
The recommendations proposed in the commission’s final report were much less contentious. The commission concluded that there is an urgent need to establish a Community Patent and a unified specialised patent litigation system in Europe. In addition, it welcomed recent initiatives of the European Patent Office (EPO) to accelerate certain of its prosecution procedures and ensure that only high-quality patents are granted.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Pharmaceuticals, European Commission